About NMP66? Proteins
Matritech scientists, using a research mass spectrometer, discovered the existence of certain proteins (NMP66) in the blood of breast cancer patients that were generally not present in the blood of women without detectable breast malignancy. Matritech is developing test methods for NMP66 proteins in a Proprietary Laboratory Procedure. Results of the Company's testing indicate that NMP66 proteins found in the blood of women with breast cancer may enable physicians to more effectively manage women with or at a risk for breast cancer.

The Company has entered into an agreement with Mitsubishi Kagaku Medical, Inc., a division of Mitsubishi Chemical (Mitsubishi), to serve as our clinical laboratory partner for a Proprietary Laboratory Service. Under terms of the agreement, Mitsubishi has first right of refusal to acquire distribution rights for the Japanese market to any Lab Test Kits or Point-of-Care Test Devices for NMP66 proteins that Matritech may develop. All of the blood specimens for use in generating reproducible and controlled clinical data prior to launching a Proprietary Lab Procedure have been collected. Matritech's scientists are optimizing the test methods for NMP66.  It is Matritech's goal to begin clinical testing after completion of test method development.

About Breast Cancer
Breast cancer is the most common cancer among women, other than skin cancer. It is the second leading cause of cancer death in women, after lung cancer. According to the American Cancer Society, about 215,990 women in the United States will be found to have invasive breast cancer in 2004. About 40,110 women will die from the disease this year. Right now there are slightly over 2 million women living in the U.S. who have been treated for breast cancer.